Introduction {#sec1_1}
============

*Helicobacter pylori* is a Gram-negative bacterium found in the human stomach. It was identified in the early eighties by Australian scientists Barry Marshall and Robin Warren, who found that it was present in patients with chronic gastritis and gastric ulcers, conditions that were not previously believed to have a microbial cause. It is also linked to the development of duodenal ulcers and gastric cancer. However, over 80% of individuals infected with the bacterium are asymptomatic, and it has been postulated that it may play an important role in the natural stomach ecology \[[@B1]\].

The traditional first-line treatment regimens for *H. pylori* often include metronidazole or clarithromycin as the backbone of antibiotic therapy. Unfortunately, metronidazole and clarithromycin are associated with significant patterns of resistance, with in vitro resistance to these antibiotics being reported as high as 40 and 13%, respectively \[[@B2], [@B3]\]. Nitazoxanide is a newer nitrothiazole benzamide compound notable for its activity in treating both intestinal protozoa and helminthic infections, with a low range of minor adverse effects \[[@B4]\].

Nitazoxanide has been reported to be effective against a broad range of parasites, including *Giardia lamblia*, *Entamoeba histolytica*, *Cryptosporidium parvum* and *Ascaris lumbricoides* \[[@B5]\]. The antiprotozoal activity of nitazoxanide is believed to be due to interference with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction, which is essential to anaerobic energy metabolism \[[@B6]\]. The US Food and Drug Administration (FDA) approved the oral suspension of nitazoxanide in December 2002 for the treatment of diarrhea caused by Cryptosporidium spp. and *G. lamblia* in pediatric patients. The first research on the antiviral effects of nitazoxanide was published in 2006 \[[@B7], [@B8]\]. Tizoxanide (the active metabolite of nitazoxanide) showed a cytoprotective effect in rotavirus-infected cells in studies carried out in vitro \[[@B7]\]. Double-blind, placebo-controlled trials in children and adults have shown a significant reduction in the median duration of diarrhea from the first dose of nitazoxanide administration in comparison with placebo \[[@B7], [@B8]\]. With the increased resistance and high prevalence of *H. pylori* infection in South Texas, an effective alternative regimen to the standard of care is warranted and desirable. The purpose of this review is to report our clinical experience using an alternative multi-drug therapy for the treatment of pediatric *H. pylori* infection.

Methods {#sec1_2}
=======

Study Design and Population {#sec2_1}
---------------------------

Charts were identified for patients who were treated between January 1, 2008 and December 31, 2013 with an ICD-9-CM code 041.86 *(H. pylori)* and who underwent elective endoscopy. Patients included in the review were described to suffer from the following clinical symptoms: chronic abdominal pain; chronic nausea or vomiting, chronic gastroesophageal reflux disease; chronic diarrhea; persistent bloating or flatulence; anal pruritus; nocturnal teeth grinding; gross or occult intestinal bleeding; and most importantly feeding problems with or without weight loss. Chronic as defined clinically is usually greater than 1 or 2 months of symptoms (American Academy of Pediatrics). All patients included in the chart review were treated with a combination of nitazoxanide twice daily for 3 days and a 3rd-generation cephalosporin antibiotic (cefixime in the majority) once daily and a macrolide antibiotic (azithromycin) once daily for 7--10 days plus a proton pump inhibitor (PPI) once daily for 30 days. Clinical cure was defined as a negative urea breath test with resolution of symptoms on the subsequent visit at no more than 4 months following antimicrobial drug therapy initiation. Patients without follow-up urea breath test were evaluated for clinical response and resolution of presentation symptoms.

Patients excluded from the analysis were those who failed to return for follow-up or had incomplete information in the chart. Exclusion criteria consisted of persistence or recurrence of infection within 4 months of initiation of the original drug therapy.

Definitions {#sec2_2}
-----------

Clinical cure was assessed no greater than 4 months after initiation of the aforementioned combination drug therapy. Clinical cure was determined to have been achieved if the patient was free from all inclusion criteria signs and symptoms as described in the methodology. Moreover, to avoid confounding medical problems, patients had to not be receiving any course of antibiotics for any other medical condition. Failure to achieve any of these endpoints was by definition clinical failure.

Assessment {#sec2_3}
----------

All patients included in the review underwent an elective esophagogastroduodenoscopy endoscopic evaluation during which tissue samples were obtained for evaluation, which included histological determination of *H. pylori* infection. Visual assessment of the characteristic *H. pylori* nodularity and erosive or ulcer disease warranted empiric therapy pending histopathology confirmation.

Results {#sec1_3}
=======

There were 112 charts identified for the period in question that represented 127 individual occurrences for evaluation in the review. Of these, 111 occurrences met all of the criteria for inclusion in the review. Table [1](#T1){ref-type="table"} shows the simple demographics for the patients included in this review. The clinical success rate for this series of patients using the new drug regimen as described is shown in table [2](#T2){ref-type="table"}. The success rate for the new therapy combination prescribed as defined prior to the review was 99 out of 111 cases (89.2%). The drug therapy assessed consisted of nitazoxanide, azithromycin and cefixime. In six cases and one case respectively, ceftibuten and cefdinir were substituted for cefixime. Table [3](#T3){ref-type="table"} shows the dosing used for the 111 cases reported. Nitazoxanide suspension (100 mg/5 ml) was used in 66 cases (59.5%) while the 500 mg tablet was prescribed for the remaining 45 patients (40.5%).

There were no serious adverse events observed or reported during the treatment course for any patient. Approximately 10% of patient charts to some degree reflected a complaint of nausea, vomiting or abdominal cramps during the time of active drug therapy. The charts for the twelve cases defined as clinical failures all reflected persistence of mild to moderate abdominal pain, nausea and/or vomiting during the entire post-treatment course up to and beyond 4 months. There was a single case of facial rash reported in one patient who was among the twelve characterized as clinical failures. As the drug regimen used for this series of patients included four drugs, it was difficult to attribute causality to any single agent.

Limitation {#sec2_4}
----------

Endoscopic visual confirmation of suspected *H. pylori* (via Olympus esophagogastroduodenoscopy endoscope with HDTV; colored photos attached to patient chart) with peptic erosive or ulcer disease was relied upon for prompt treatment in the light of the patients' chronic gastrointestinal signs and symptoms and risk factors noted in the clinical history. In addition, in community-based clinical practice, systematic protocols require more extensive planning with trained personnel. However, despite the inherent limitations of this retrospective review, analysis of data demonstrated significant clinical improvement within a significant period of time post diagnosis and initiation of treatment.

Discussion {#sec1_4}
==========

*H. pylori* is a Gram-negative, spiral bacterium situated on the epithelial surface of the stomach \[[@B6]\]. It is thought to be the most common bacterial infection worldwide \[[@B9]\]. Virtually all persons infected by this organism develop gastritis, a signature feature of which is the capacity to persist for decades, leading to chronic inflammation of the underlying mucosa \[[@B6]\]. The organism can resist the harsh acidic environment of the stomach due to its high urease activity; urease converts the urea present in gastric juice to alkaline ammonia and carbon dioxide, thereby raising the pH of the stomach and allowing it to thrive \[[@B6]\]. In chronic disease states as well as in high-risk and immunocompromised populations, *H. pylori* infection leads to peptic ulcer and gastric cancer \[[@B6]\].

In the past, drug regimens that included a PPIs in combination with several antibiotics such as clarithromycin, amoxicillin and metronidazole given 7--14 days in divided doses were very successful for *H. pylori* eradication \[[@B10], [@B11]\]. Unfortunately, there are reports of reduced efficacy of these combinations as a result of the emerging problem of antibiotic resistance both in developing and developed countries \[[@B12]\]. This has led to the use of newer and arguably more powerful antibiotic combinations that include tetracycline, doxycycline, clarithromycin and levofloxacin, to name a few.

The use of nitazoxanide in the treatment of *H. pylori* as part of a multi-drug regimen has been described by others \[[@B13]\]. An investigational four-drug regimen for the ulcer-causing *H. pylori* infection led to a significantly higher eradication rate than the current standard in previously untreated patients in a multi-center, randomized trial reported in 2009 during the Annual Meeting of the American College of Gastroenterology. The new four-drug treatment, known as LOAD, comprises levofloxacin, omeprazole (Prilosec), nitazoxanide (Alinia) and doxycycline. It was tried against the normal three-drug regimen, known as LAC, which stands for lansoprazole (Kapidex, Prevacid), amoxicillin and clarithromycin. Seven-day and 10-day courses of the LOAD regimen led to eradication rates of about 90%, compared with 75% in patients treated with the LAC regimen. Adverse event rates were similar, except for abdominal pain, which occurred significantly less often under the LOAD regimen. The utility of nitazoxanide as monotherapy in the treatment of *H. pylori* gastritis has also been described by others, but is not the focus of our review and so will not be addressed here.

In this report, a pediatric clinical experience of empiric use of nitazoxanide (for suspected metronidazole-resistant strains) in combination with a 3rd-generation cephalosporin (for suspected amoxicillin resistance), azithromycin (for suspected clarithromycin resistance) and a PPI were prescribed to manage *H. pylori* peptic ulcer and erosive disease post endoscopy. Nitazoxanide, a nitrothiazolyl-salicylamide compound, was first described by Rossignol and Cavier \[[@B14]\]. The selection of nitazoxanide was based on its reported broad spectrum of activity against microaerobic and anaerobic bacteria, anaerobic protozoa and helminths \[[@B15], [@B16]\]. Alinia^®^ tablets and Alinia^®^ oral suspension contain the active ingredient nitazoxanide, a synthetic antiprotozoal agent for oral administration \[[@B17]\]. Following oral administration of nitazoxanide, maximum plasma concentrations of the active metabolites tizoxanide and tizoxanide glucuronide are observed within 1--4 h \[[@B17]\]. The parent nitazoxanide is not detected in plasma \[[@B17]\]. Following oral administration in humans, nitazoxanide is rapidly hydrolyzed to an active metabolite, tizoxanide (desacetyl-nitazoxanide) \[[@B17]\]. Tizoxanide then undergoes conjugation, primarily by glucuronidation \[[@B17]\]. In vitro metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes \[[@B17]\]. Tizoxanide is excreted in urine, bile and feces, and tizoxanide glucuronide is excreted in urine and bile \[[@B17]\]. Approximately two-thirds of the oral dose of nitazoxanide is excreted in the feces and one-third in the urine \[[@B17]\].

The antiprotozoal activity of nitazoxanide is believed to be due to interference with the PFOR enzyme-dependent electron transfer reaction in a unique non-competitive binding by targeting thiamine pyrophosphate (cofactor to PFOR), which disrupts pyruvate oxidation and energy production, leading to death of the organism \[[@B17]\]. This mechanism of action is postulated to avoid mutation-based drug resistance \[[@B17]\]. Nitazoxanide also disrupts two other enzyme systems: nitroreductases and protein disulfide isomerases, which are minor but essential to anaerobic energy metabolism \[[@B18]\]. These inhibitory actions may account for its activity against *H. pylori* infection \[[@B18]\].

Nitazoxanide oral suspension (for patients 1 year of age and older) and tablets (for patients 12 years and older) are indicated for the treatment of diarrhea caused by *G. lamblia* or *C. parvum*. In vitro, nitazoxanide has activity against anaerobic bacteria (Bacteroides spp. and Clostridium spp.) and some aerobic Gram-positive bacteria and viruses \[[@B17]\]. The standard dosing frequency of nitazoxanide is every 12 h with food for 3 days \[[@B17]\]. It is the short 3-day course of nitazoxanide, coupled with its very favorable safety profile, that makes the drug attractive for empiric drug therapy for the treatment of *H. pylori*.

This retrospective study demonstrates a clinical success similar to that reported by Basu et al. \[[@B13]\] for the LOAD protocol (89 vs. 90%, respectively). It describes clinical success in the use of a combination regimen of nitazoxanide, azithromycin, a 3rd-generation cephalosporin, and a PPI in the treatment of endoscopically diagnosed *H. pylori* peptic ulcer or erosive disease in chronically symptomatic children. Unlike the LOAD protocol, the regimen of nitazoxanide used was and is consistent with the current label of twice daily administration for 3 days. The drug is well tolerated and use of the liquid formulation in children offers the advantage of easy, well-accepted administration of a pleasant-flavored liquid.

Nitazoxanide in the treatment of *H. pylori* is not an approved indication yet. However, the clinical experience described appears to support the synergistic action of nitazoxanide with other antibiotics, especially in clinically suspected multi-drug resistance to metronidazole, amoxicillin and clarithromycin. It is well tolerated, with the most common adverse events reported regardless of causality assessment being abdominal pain (6.6%), diarrhea (4.2%), headache (3.1%) and nausea (3.0%). The oral suspension formulation of nitazoxanide in a pink pleasant strawberry flavor presents a more palatable administration especially in children.

This clinical experience presents a viable treatment option in community-based clinical settings where multiple drug-resistant strains of *H. pylori* are suspected in a high-risk population. The ongoing emergence of multiple drug-resistant organisms is a serious public health dilemma. The results of this study suggest an alternative regimen that can readily be initiated in cases where immediate treatment is a priority, pending further diagnostic studies. In the pediatric population where chronic gastrointestinal disease produces profound feeding and nutritional deficiencies, initiation of therapy in the interest of preventing and reversing immune deficiency is of critical importance.

Despite the inherent limitations of this retrospective study, the efficacy of a 3-day course of nitazoxanide is worth additional investigation to clearly determine its efficacy in the treatment of *H. pylori* peptic ulcer disease and prevention of gastric cancer.
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###### 

Patient demographics

  -------------------- ------------
  Male                 65 (58.6%)
  Female               46 (41.4%)
                       
  Age range, years     1--21
  Average age, years   10.04
  -------------------- ------------

###### 

Response rate to multi-drug therapy

  ------------------ -------------
  Patients           111 (100%)
  Clinical cure      099 (89.2%)
  Clinical failure   012 (10.8%)
  ------------------ -------------

###### 

Antibiotic therapy selection and distribution

                 Frequency     Average dose, mg   Duration, days   Number received
  -------------- ------------- ------------------ ---------------- -----------------
  Nitazoxanide   twice daily   327.5              03               111
  Azithromycin   once daily    215.1              10               111
  \+                                                               
  Cefixime       once daily    278.8              10               104
  Ceftibuten     once daily    246.0              10               006
  Cefdinir       twice daily   125.0              10               001
